EUCTR2009-010902-13-AT进行中（未招募）不适用
Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder - HMGF
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Male and female outpatients at least 65 years old presenting with GAD based on the DSM-IV TR diagnostic criteria. The patient must suffer from GAD and not from an adjustment disorder or anxiety disorder NOS. Symptoms of GAD should not be situational in nature.
- •[2] Have a MMSE score of at least 24 at Visit 1.
- •[3] Have a CGI-Severity score of =4 at Visit 1 and Visit 2.
- •[4] Have a CAS score of =9, no item in the RDS may be >3, and the CAS score must be greater than the RDS at Visit 1.
- •[5] Have a HADS anxiety subscale score of =10 at Visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[8] Have any current and primary DSM-IV TR Axis I diagnosis other than GAD, with the exception of comorbid social phobia or specific phobia.
- •[9] The presence of an Axis II disorder, or history of antisocial behavior, or patients who, in the opinion of the investigator, are poor medical or psychiatric risks for study compliance.
- •[10] Have organic mental disorder or mental retardation diagnosis.
- •[11] Currently use benzodiazepine or have used benzodiazepine 14 days prior to Visit 2.
- •[12] Are judged clinically to be at serious risk of harm to self or others.
- •[15] Have a history of alcohol or any psychoactive substance abuse or dependence (as defined in the DSM-IV TR) within the past 6 months.
- •[16] Excessively use caffeine, in the opinion of the investigator.
- •[17] Have a positive UDS for any substances of abuse at Visit 1.
- •[18] Have a serious medical illness, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require hospitalization within 6 months, in the opinion of the investigator. Clinically significant laboratory abnormalities are those that, in the judgment of the investigator, indicate a serious medical problem.
- •[19] Have any acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C).
- •[20] Have an abnormal thyroid-stimulating hormone (TSH) concentrations (outside the reference range of the performing laboratory).
- •[21] Have initiated psychotherapy or changed intensity of psychotherapy or other non-drug therapies (such as acupuncture or hypnosis) within 6 weeks prior to enrollment or at any time during the study.
- •[22] Have taken any excluded medication within 7 days prior to Visit 2.
- •[23] Have been treated with a monoamine oxidase inhibitor (MAOI) or fluoxetine within 30 days of Visit 2 or potentially need to use an MAOI during the study or within 5 days of discontinuation of study drug.
- •[24] Exhibit a lack of response of the current episode of GAD to 2 or more adequate trials of antidepressants, benzodiazepines, or other anxiolytics at a clinically appropriate dose for a minimum of 4 weeks.
- •[25] Have a history of severe allergies, hypersensitivity to duloxetine or to any of the inactive ingredients; multiple adverse drug reactions; transcranial magnetic stimulation (TMS); history of seizures; or history of psychosurgery or electroconvulsive therapy (ECT) within 12 months.
- •[26] Have discontinued hormone replacement therapy within the previous 3 months.
- •[29] Have uncontrolled narrow-angle glaucoma.
研究者
相似试验
进行中（未招募）
不适用
Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder - HMGFGeneralized anxiety disorder (GAD)MedDRA version: 14.0Level: LLTClassification code 10018105Term: Generalized anxiety disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2009-010902-13-DEEli Lilly and Company288
进行中（未招募）
1 期
Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder - HMGFGeneralized anxiety disorder (GAD)MedDRA version: 12.1 Level: LLT Classification code 10018105 Term: Generalized anxiety disorderEUCTR2009-010902-13-GBEli Lilly and Company288
进行中（未招募）
不适用
Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression - HMFAMajor Depressive Disorder in elderly patientsMedDRA version: 9.1Level: LLTClassification code 10012378Term: DepressionEUCTR2008-001829-33-FREli Lilly and Company300
进行中（未招募）
1 期
Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizadaDuloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder - HMGFTrastorno de ansiedad generalizadaGeneralized anxiety disorder (GAD)MedDRA version: 11Level: LLTClassification code 10018105Term: Trastorno de ansiedad generalizadaEUCTR2009-010902-13-ESILLY S.A.288
招募中
3 期
Comparison of the effectiveness of duloxetine and nortriptyline in the treatment of pain in rheumatoid arthritis patientspain.IRCT20220901055848N1Shahid Beheshti University of Medical Sciences54